It has been demonstrated that stem cell factor (SCF) and its receptor KIT play key roles in the differentiation, proliferation, survival, migration and activation of mast cells, which in turn play a central role in the development of IgE-mediated allergic diseases, including allergic urticaria and food allergy.
Researchers from Suzhou Alphama Biotechnology Co. Ltd. have reported the discovery of a novel selective KRAS G12C inhibitor, 143D, as a potential new anticancer drug.
Previous research has demonstrated that overexpression or gain-of-function mutations of enhancer of zeste homolog 2 (EZH2) are significantly associated with tumor cell proliferation of a number of cancers.
Sickle cell disease (SCD) is autosomal recessive disorder caused by mutations in the β-globin gene, and induction of fetal γ-globin is considered an established therapeutic strategy for the treatment of this disease. A research team led by scientists at Kyorin Pharmaceutical Co. Ltd. has discovered RK-701, a small-molecule inhibitor of G9a and G9a-like protein (GLP) as a potential therapeutic agent for SCD.
Evidence has suggested free fatty acid receptor 1 (FFAR1), also known as GPR40, as a promising therapeutic target in the treatment of type 2 diabetes, since its activation in pancreatic β cells promotes insulin secretion in a glucose concentration-dependent manner.
Researchers from Kbluebio Inc. and affiliated organizations recently reported the discovery and preclinical evaluation of a novel prohibitin-2 (PHB2) ligand as a potential candidate for the treatment of multiple myeloma (MM).
Researchers from Taipei Medical University presented the discovery of novel store-operated calcium channel (SOC) inhibitors as potential anticancer candidates. Synthesis and optimization of a series of difluorobenzamide derivatives led to the discovery of MPT-0M004 as the lead candidate with promising SOC inhibitory activity. In vitro, both migration and invasion of colorectal cancer cells were significantly suppressed after 48 hours of treatment with MPT-0M004, with the growth inhibitory effect of the compound being similar to that seen for the reference SOC inhibitor.
RSS
